aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman

ATYR Investors with Losses Encouraged to Contact Hagens Berman

SAN FRANCISCO, Oct. 14, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.

Read more at prnewswire.com